TMO

Thermo Fisher Scientific
D

TMO

Arincen67/100B
706.32
USD
7.96
(1.14%)
Post Trading·709.98USD+3.66(+0.52%)
Last updated: · Delayed 15 min
Fair value599.09Plus+18%433Price 706.32754
Q4 FY2026 · Earnings report
EPS estimate 7.13Revenue estimate 12.84B
OverviewFinancialsForecastEarningsDividendsCompany

Thermo Fisher Scientific revenue 1985–2026

Thermo Fisher Scientific's revenue in Q3 FY2026, the three months to 26 September 2026, was 12.14B USD, up 9.1% on the same quarter a year before. Thermo Fisher Scientific's revenue over the last twelve months was 47.35B USD, up 8.3% on the twelve months before. In fiscal year 2025 it was 44.56B USD, up 3.9% on the year before.

Last updated 3 Nov 2026 · Next report 4 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM26 Sept 202647.35B+8.27%19.62B7.08B
FY202531 Dec 202544.56B+3.91%18.24B6.74B
FY202431 Dec 202442.88B+0.05%17.73B6.34B
FY202331 Dec 202342.86B-4.58%17.19B6.00B
FY202231 Dec 202244.92B+14.55%19.01B6.95B
FY202131 Dec 202139.21B+21.71%19.63B7.73B
FY202031 Dec 202032.22B+26.14%16.03B6.38B
FY201931 Dec 201925.54B+4.86%11.34B3.70B
FY201831 Dec 201824.36B+16.45%10.99B2.94B
FY201731 Dec 201720.92B+14.47%9.68B2.23B
FY201631 Dec 201618.27B+7.71%8.58B2.02B
FY201531 Dec 201516.97B+0.45%7.84B1.98B
FY201431 Dec 201416.89B+29.02%7.89B1.89B
FY201331 Dec 201313.09B+4.64%5.63B1.27B
FY201231 Dec 201212.51B+6.69%5.41B1.18B
FY201131 Dec 201111.73B+8.69%4.87B1.33B
FY201031 Dec 201010.79B+6.72%4.27B1.04B
FY200931 Dec 200910.11B-3.70%4.07B850.30M
FY200831 Dec 200810.50B+7.71%4.24B994.20M
FY200731 Dec 20079.75B+157.05%3.89B761.10M
FY200631 Dec 20063.79B+44.00%1.69B168.94M
FY200531 Dec 20052.63B+19.36%1.24B223.22M
FY200431 Dec 20042.21B+5.19%1.02B361.84M
FY200331 Dec 20032.10B+0.52%948.02M200.01M
FY200231 Dec 20022.09B-4.65%927.38M309.73M
FY200131 Dec 20012.19B-4.05%958.62M-781.00K
FY200031 Dec 20002.28B-7.72%1.02B-36.11M
FY199931 Dec 19992.47B-36.11%1.21B-174.60M
FY199831 Dec 19983.87B+8.69%1.84B181.90M
FY199731 Dec 19973.56B+21.34%1.72B239.30M
FY199631 Dec 19962.93B+32.85%1.39B190.80M
FY199531 Dec 19952.21B+39.24%1.08B140.10M
FY199431 Dec 19941.59B+26.85%719.00M103.40M
FY199331 Dec 19931.25B+31.69%536.60M76.60M
FY199231 Dec 1992949.00M+17.82%369.20M59.20M
FY199131 Dec 1991805.50M+13.77%295.30M47.10M
FY199031 Dec 1990708.00M+22.28%265.00M33.90M
FY198931 Dec 1989579.00M+15.66%194.90M24.60M
FY198831 Dec 1988500.60M+30.57%174.90M20.10M
FY198731 Dec 1987383.40M+15.62%134.70M18.10M
FY198631 Dec 1986331.60M+24.80%112.30M14.30M
FY198531 Dec 1985265.70M—91.40M9.60M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Thermo Fisher Scientific revenue growth by segment

Q3 FY2026 against Q3 FY2025

Product6.75B
—
Service5.38B
+16.2%
Product, Consumables4.87B
—
Product, Instruments1.88B
—

Thermo Fisher Scientific revenue by segment over time

Consumables Service Instruments Specialty Diagnostics Analytical Instruments Life Sciences Solutions Laboratory Products and Services
Fiscal yearConsumablesServiceInstrumentsSpecialty DiagnosticsAnalytical InstrumentsLife Sciences SolutionsLaboratory Products and Services
FY202518.66B +6.1%18.59B +4.2%7.30B -1.9%— — — —
FY202417.59B -0.1%17.85B +1.3%7.45B -2.6%— — — —
FY202317.60B -14.7%17.61B +7.6%7.65B -3.5%— — — —
FY202220.62B -8.8%16.37B +84.9%7.92B +2.2%— — — —
FY202122.61B +22.0%8.85B +28.0%7.75B +14.4%— — — —
FY202018.53B +41.3%6.91B +14.3%6.78B +6.1%— — — —
FY201913.11B +4.2%6.05B +10.1%6.39B +1.5%— — — —
FY201812.58B 5.49B 6.29B — — — —
FY2017— — — 3.49B +4.4%4.85B 5.73B 8.00B
FY2016— — — 3.34B +2.9%— — —

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Thermo Fisher Scientific's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.